revenu ep well estim guidanc rais line
manag posit futur biopharma divis
ep estim consensu ep guidanc
rais prior last publish estim
review
sale estim
consensu product beat estim includ ibranc lipitor
vydaquel patient receiv vyndamax date
ttr-cardiomyopathi inlyta xeljanz xtandi xalkori prevnar chantix zyvox
viagra norvasc combin forecast product
estim includ lyrica eliqui premarin
celebrex sutent combin forecast told
biopharma revenu beat upjohn sale beat consum sale
includ one month jv gsk complet
estim revenu guidanc rais narrow prior
last publish estim review
gpm estim
estim sg forecast net non-oper
expens estim tax rate
estim share count estim
cog rang prior vs si expens
prior vs expens updat
prior vs net income/expens
unchang approxim incom tax rate unchang
approv ttr-cardiomyopathi xtandi approv mhspc pdufa dec
abrocitinib phase data ad vs dupix compani believ itch profil
shown superior upjohn divestitur complet complet list
event shown follow page
pleas see page report import disclosur
cowen compani
expens inc mm cowen
cowen compani
cowen compani
cowen
cowen compani
cowen
cowen compani
cowen compani
cowen compani
time frameev pearl data nsai resisti bcpneumococc vaccinephas ii data pediatr late data cv outcom studi cvregulatorybiosimilar humirau /eu approv bsufa biosimilar rituxan eu approvaltafamidi vyndaqel eu approv ttr-cardiomyopathytanezumabu file dose oa pain late approv mhspc pdufa dec data atop dermat vs dupilumab jade compar full ph data atop dermat posit top-lin sept data nsclc javelin lung tripletphas data solid tumorsbavencio doubletphas datac difficil vaccinephas dataibrancephas data penelope-b post neoadjuv high risk bcphase data palla adjuv intermediate/high risk bcpneumococc vaccinephas data w/sangamo initi phase hemophilia array approv braf mcrceucrisaeu approv atop dermatitispneumococc vaccineregulatori file adultscorporateupjohn divestiturecomplet cowen
valuat methodolog primarili base current year forward price-to-earnings multipl
also consid total return/p ratio market cap/fre cash flow metric
failur pipelin product intellectu properti challeng econom sensit
price pressur and/or weaken consum demand develop market econom
and/or polit uncertainti emerg market chang tax law outlook
dividend fluctuat foreign exchang rate
risk includ success pipelin product patent expir greater
expect impact ep success streamlin and/or separ busi
structur outcom potenti
author research report herebi certifi view express research report accur reflect person view subject
secur issuer ii part compens relat directli indirectli specif recommend view express report
